Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia

G. Franceschini, F. Bernini, S. Michelagnoli, S. Bellosta, V. Vaccarino, C. Torre, F. Pazzucconi, R. Fumagalli, C. R. Sirtori

Research output: Contribution to journalArticlepeer-review


The regulation of cellular LDL metabolism by hypertriglyceridemic LDL was tested before and after treatment with acipimox, a nicotinic acid derivative, in 11 type IV hyperlipidemic patients. Large, less dense LDL particles were found in plasma after acipimox treatment. HDL subfractions were only slightly modified, with an increase of dense, cholesteryl ester-enriched and triglyceride-poor HDL3 particles. The LDL (B, E) receptor activity in human skin fibroblasts of LDL isolated before and after treatment was also evaluated. Hypertriglyceridemic LDL proved rather inefficient in regulating receptor activity, with a close to 30% lower capacity than normal LDL to inhibit receptor-mediated uptake and degradation of125I-LDL. This abnormality was fully corrected after acipimox. The reported findings indicate that acipimox treatment in type IV patients can normalize the defective interaction of hypertriglyceridemic LDL with the LDL (B, E) receptor.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Issue number1
Publication statusPublished - Jan 1991


  • acipimox
  • Hypertriglyceridemia
  • LDL receptor
  • low-density lipoproteins
  • nicotinic acid

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia'. Together they form a unique fingerprint.

Cite this